Abstract
Pre-harvest autologous blood collection from bone marrow (BM) donors is performed to meet potential post-operative transfusion needs. This study examines the impact of autologous blood transfusion on BM donor’s health and safety. The study included first-time unrelated BM donors from the United States whose BM harvest was facilitated by the National Marrow Donor Program (NMDP) centers between 2006 and 2017. Examination of 7024 BM donors revealed that 60% received at least one unit of autologous blood. The donors who received autologous blood were older, had lower hemoglobin pre-harvest, underwent longer duration of anesthesia, and higher volume BM harvest. Only donors who underwent high-volume BM harvest, defined as a BM harvest volume >27% of donor’s blood volume, benefited from autologous transfusion. After a high-volume BM harvest, autologous blood transfusion was shown to decrease grade 2 to 4 collection-associated toxicities within 48 h of BM donation (p = 0.010) and shorten the time to donor-reported “complete” recovery from donation-associated symptoms (p < 0.001). Therefore, autologous transfusion could be avoided as support of marrow donation in the majority of unrelated BM donors and should be limited to cases where the planned BM harvest volume is expected to exceed 27% of donor’s blood volume.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Change history
08 June 2020
A Correction to this paper has been published: https://doi.org/10.1038/s41409-020-0963-9
References
Wallace EL, Surgenor DM, Hao HS, An J, Chapman RH, Churchill WH. Collection and transfusion of blood and blood components in the United States, 1989. Transfusion. 1993;33:139–44.
Wallace EL, Churchill WH, Surgenor DM, Cho GS, McGurk S. Collection and transfusion of blood and blood components in the United States, 1994. Transfusion. 1998;38:625–36.
Busch MP, Young MJ, Samson SM, Mosley JW, Ward JW, Perkins HA. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The Transfusion Safety Study Group. Transfusion. 1991;31:4–11.
Zou S, Stramer SL, Dodd RY. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfus Med Rev. 2012;26:119–28.
Dorsey KA, Moritz ED, Steele WR, Eder AF, Stramer SL. A comparison of human immunodeficiency virus, hepatitis C virus, hepatitis B virus, and human T-lymphotropic virus marker rates for directed versus volunteer blood donations to the American Red Cross during 2005 to 2010. Transfusion. 2013;53:1250–6.
Kattermann R, Gille H. [Total protein determination in lipemic or icteric specimens]. Med Lab (Stuttg). 1975;28:130–1.
Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev. 2007;21:327–48.
Goel R, Tobian AAR, Shaz BH. Non-infectious transfusion associated adverse events and their mitigation strategies. Blood. 2019;133:1831–9.
Domen RE. Adverse reactions associated with autologous blood transfusion: evaluation and incidence at a large academic hospital. Transfusion. 1998;38:296–300.
Vamvakas EC. Meta-analysis of randomized controlled trials comparing the risk of postoperative infection between recipients of allogeneic and autologous blood transfusion. Vox Sang. 2002;83:339–46.
Goldman M, Rémy-Prince S, Trépanier A, Décary F. Autologous donation error rates in Canada. Transfusion. 1997;37:523–7.
Etchason J, Petz L, Keeler E, Calhoun L, Kleinman S, Snider C, et al. The cost effectiveness of preoperative autologous blood donations. N. Engl J Med. 1995;332:719–24.
Tretiak R, Laupacis A, Rivière M, McKerracher K, Souêtre E. Cost of allogeneic and autologous blood transfusion in Canada. Canadian Cost of Transfusion Study Group. Can Med Assoc J. 1996;154:1501–8.
Whitaker BI, Hinkins S. The 2011 national blood collection and utilization survey report. US Department of Health and Human Services; 2011.
Janssen MP, van Hoeven LR, Rautmann G. Trends and observations on the collection, testing and use of blood and blood components in Europe. 2001–11 report. Council of Europe: Strasbourg; 2015.
Arora K, Kelley J, Martinez F, Tholpady A. Preoperative autologous blood collection before bone marrow harvests in haploidentical related donors: is it justified? Transfusion. 2018;58:1618–25.
Parkkali T, Juvonen E, Volin L, Partanen J, Ruutu T. Collection of autologous blood for bone marrow donation: how useful is it? Bone Marrow Transplant. 2005;35:1035–9.
Mijovic A, Britten C, Regan F, Harrison J. Preoperative autologous blood donation for bone marrow harvests: are we wasting donors’ time and blood? Transfus Med. 2006;16:57–62.
Manuel SP, Spitzer TR, Ishizawa Y. Preoperative autologous blood donation in healthy bone marrow donors contributes to pre-procedure anemia. Bone Marrow Transplant. 2017;52:1191–3.
Pulsipher MA, Chitphakdithai P, Logan BR, Shaw BE, Wingard JR, Lazarus HM, et al. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood. 2013;121:197–206.
Miller JP, Perry EH, Price TH, Bolan CD, Karanes C, Boyd TM, et al. Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. Biol Blood Marrow Transplant. 2008;14:29–36.
Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51:224–32.
Zhang X, Loberiza FR, Klein JP, Zhang M-JA. SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model. Comput Methods Prog Biomed. 2007;88:95–101.
Brecher ME, Goodnough LT. The rise and fall of preoperative autologous blood donation. Transfusion. 2001;41:1459–62.
Gouëzec H, Ferré N, Hervé F, Lapart C, Leberre C, Bernard M, et al. [Suitability of autologous blood donation before bone marrow donation]. Transfus Clin Biol. 2015;22:71–75.
Worel N, Buser A, Greinix HT, Hägglund H, Navarro W, Pulsipher MA, et al. Suitability criteria for adult related donors: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation Standing Committee on Donor Issues. Biol Blood Marrow Transplant. 2015;21:2052–60.
Bunn HF. Pathophysiology of the anemias. In: Jameson JL, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalzo J, editors. Harrison’s principle of internal medicine. 20th Edn. New York: McGraw Hill-Education; 1991.
Kiss JE, Brambilla D, Glynn SA, Mast AE, Spencer BR, Stone M, et al. Oral iron supplementation after blood donation: a randomized clinical trial. JAMA. 2015;313:575–83.
Spitzer TR, Sugrue MW, Gonzalez C, O’Donnell P, Confer D, Fuchs E, et al. Transfusion practices for bone marrow harvests: a survey analysis from the AABB Bone Marrow Quality Improvement Initiative Working Group. Bone Marrow Transplant. 2017;52:1199–1200.
Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, et al. Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage. JAMA. 2016;316:2025–35.
Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2016;10:CD002042.
Styczynski J, Balduzzi A, Gil L, Labopin M, Hamladji R-M, Marktel S, et al. Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. Blood. 2012;119:2935–42.
Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, et al. Higher risks of toxicity and incomplete recovery in 13- to 17-year-old females after marrow donation: RDSafe Peds results. Biol Blood Marrow Transplant. 2019;25:955–64.
Acknowledgements
The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 1U24HL138660 from NHLBI and NCI; a contract HHSH250201700006C with Health Resources and Services Administration (HRSA/DHHS); three Grants N00014-17-1-2388, N00014-17-1-2850, and N00014-18-1-2045 from the Office of Naval Research; and grants from Adaptive Biotechnologies; *Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; *Chimerix, Inc.; *CytoSen Therapeutics, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Gilead Sciences, Inc.; HistoGenetics, Inc.; Immucor; *Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Karius, Inc.; Karyopharm Therapeutics, Inc.; *Kite Pharma, Inc.; Medac, GmbH; *Mediware; The Medical College of Wisconsin; *Merck & Co, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; Mundipharma EDO; National Marrow Donor Program; Novartis Pharmaceuticals Corporation; PCORI; *Pfizer, Inc; *Pharmacyclics, LLC; PIRCHE AG; *Sanofi Genzyme; *Seattle Genetics; Shire; Spectrum Pharmaceuticals, Inc.; St. Baldrick’s Foundation; Swedish Orphan Biovitrum, Inc.; *Takeda Oncology; and University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. *Corporate Members
Author information
Authors and Affiliations
Contributions
NF, HSM, JRW, and BES designed the study, developed the protocol, interpreted the data, and wrote the manuscript. BRL and JAS designed the study, analyzed and interpreted the data, and generated the figures. AM, MB, AMB, SC, MAD, KE, HF, SG, UG, NRK, RTK, KAK, HML, JLL, MN, PVO, RFO, SNR, BNS, RS, SS, MMS, TS, MS, JAY, ML, JS, MAP, NNS, GES,and DLC participated in the design of the study and edited the final manuscript. The final manuscript was reviewed and approved by all authors.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Farhadfar, N., Murthy, H.S., Logan, B.R. et al. Impact of autologous blood transfusion after bone marrow harvest on unrelated donor’s health and outcome: a CIBMTR analysis. Bone Marrow Transplant 55, 2121–2131 (2020). https://doi.org/10.1038/s41409-020-0911-8
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41409-020-0911-8
This article is cited by
-
Lateral and posterolateral iliac crest approach for bone marrow aspirate harvest in regenerative orthopedic applications
Journal of Orthopaedic Surgery and Research (2026)
-
The impact of blood donation on bone marrow harvest efficiency
Bone Marrow Transplantation (2022)
-
Declining bone marrow harvest quality over 24 years: a single institution experience
Bone Marrow Transplantation (2021)
